ClinicalTrials.gg
CompletedNCT01309789Updated Jun 28, 2017

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

A Phase 1 interventional study of brentuximab vedotin and cyclophosphamide in Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell and Lymphoma, T-cell, sponsored by Seagen Inc.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-28.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.

Enrollment
12th of 21
39 · median 44
Started
2011
the only one that year
Phase 1
6 of 21
none open now
Registered
7th of 21
by date
Lead sponsor
9 of 21
Seagen Inc.

Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 12th largest by enrollment, is the only one that started in 2011, is one of 6 in phase 1, and was the 7th registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma. It is a phase 1, open-label, dose escalation study in three arms designed to define the MTD, PK, immunogenicity, and anti-tumor activity of brentuximab vedotin in sequence and in combination with multi-agent front-line chemotherapy.

03

Conditions studied

  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, NK-cell
  • Lymphoma, T-cell

Keywords

  • Antibodies, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Drug Therapy
  • Hematologic Diseases
  • Lymphoma
  • monomethyl auristatin E
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, T-cell
  • Lymphoma, NK-cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naive CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma
  • of at least 1.5 cm
  • performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
  • Current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell lymphoma, nasal type
  • History of another primary that has not been in remission for at least 3 years
  • \<45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
  • Viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
  • Known (HIV), virus, or virus positive status
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    1

    Sequential

    Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin · Drug: vincristine

  • Experimental
    2

    Combination

    Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone

  • Experimental
    3 Brentuximab vedotin/CH-P

    Combination

    Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone

Interventions

  • 1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)

    Also known as: SGN-35

  • 750 mg/m2 IV every 3 weeks (Cycles 3-8)

  • 1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)

    Also known as: SGN-35

  • 100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)

  • 750 mg/m2 IV every 3 weeks (Cycles 1-6)

  • 50 mg/m2 IV every 3 weeks (Cycles 3-8)

  • 50 mg/m2 IV every 3 weeks (Cycles 1-6)

  • 100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)

  • 1.4 mg/m2 IV every 3 weeks (Cycles 3-8)

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and laboratory abnormalities

    Time frame: Through 1 month after last dose

Secondary outcomes

  1. Brentuximab vedotin concentration in blood

    Time frame: Through 1 month after last dose

  2. Antitherapeutic antibodies in blood

    Time frame: Through 1 month after last dose

  3. Best clinical response

    Time frame: Through 1 month after last dose

  4. Progression-free survival

    Time frame: Until disease progression or study closure

  5. Overall survival

    Time frame: Every 3 months until death or study closure

07

Study locations

11 sites
  • UAB Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • St. Francis Hospital
    Greenville, South Carolina 29601, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4000, United States
  • Seattle Cancer Care Alliance / University of Washington Medical Center
    Seattle, Washington 98109, United States
  • Christie Hospital NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Publications

  • Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18. PubMed 25135998 ↗
  • Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5. PubMed 29507077 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2013 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2011
First posted
Mar 7, 2011
Start
Feb 2011
Primary completionActual
Apr 2013
CompletionActual
Feb 28, 2017
Last update
Jun 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01309789
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Mar 7, 2011
Start date
Feb 2011
Primary completion
Apr 2013
Completion
Feb 28, 2017
Last update
Jun 28, 2017

Study contacts

Dana Kennedy, PharmD, BCOP
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion